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Control of Johne’s disease, caused by Mycobacterium avium subspecies paratuberculosis
(MAP) in ruminants using commercially available vaccine reduces production losses,
mortality, fecal shedding and histopathological lesions but does not provide complete
protection from infection and interferes with serological diagnosis of Johne’s disease
and bovine tuberculosis. At this time no recombinant antigens have been found to
provide superior protection compared to whole killed or live-attenuated MAP vaccines.
Therefore, there is a need to evaluate more candidate MAP antigens. In this study
recombinant MAP antigens MAP2698c and MAP3567 were formulated with four different
MONTANIDE™ (ISA 50V2, 61VG, 71VG, and 201VG) adjuvants and evaluated for their
ability to produce specific immune responses in vaccinated sheep. The cellular immune
response was measured with an interferon-gamma (IFN-γ) release assay and the humoral
immune response was measured by antibody detection enzyme linked immunosorbent
assay. Recombinant vaccine formulation with the antigen MAP2698c and MONTANIDE™
ISA 201VG adjuvant produced strong whole-MAP as well as MAP2698c-specific IFN-γ
responses in a high proportion of the vaccinated sheep. The formulation caused less
severe injection site lesions in comparison to other formulations. The findings from this
study suggest that the MAP2698c + 201VG should be evaluated in a challenge trial to
determine the efficacy of this vaccine candidate.
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INTRODUCTION
Johne’s disease caused by Mycobacterium avium subspecies
paratuberculosis (MAP), is an economically significant disease
of ruminant species particularly cattle and sheep (Ott et al.,
1999; Morris et al., 2006). MAP vaccines used in livestock con-
tain heat-killed (Gudair® 316F strain, Mycopar strain 18, ID-
Lelystad and 5889 Bergey) or live modified (Neoparasec-strain
316F and OSLO-strain 316F/2E) MAP cells Rosseels and Huygen
(2008). Vaccination using a currently available commercial vac-
cine reduces production loss, mortality, histopathological lesions
(Wentink et al., 1994; Griffin et al., 2009), bacterial shedding in
feces (Kormendy, 1994; Juste et al., 2009; Alonso-Hearn et al.,
2012) and extends the average life of vaccinated animals but
does not provide complete protection from infection (Reddacliff
et al., 2006; Windsor, 2006). Furthermore, the use of killed or
live-attenuated vaccine is limited mainly to sheep due to the
cross reaction it produces with the immunological diagnosis of
bovine tuberculosis in cattle (Stringer et al., 2011). Potential
inadvertent self-injection by the handler with the commercial
vaccines is also a concern due to severe injection site reac-
tions (Windsor et al., 2005; Windsor, 2006). Recombinant MAP
vaccines should have various merits over killed or attenuated
vaccines in terms of antigen production and human safety. The
most commonly evaluated recombinant proteins have been Hsp
70 (Koets et al., 2006), antigen 85, 74F, SOD, 35 kDa (Chen
et al., 2008; Kathaperumal et al., 2008; Park et al., 2008), mpt
(Heinzmann et al., 2008), 95 kDa (Bull et al., 2007), P22 (Rigden
et al., 2006), 65 kDa (Velaz-Faircloth et al., 1999), and 16.8 kDa
(Kadam et al., 2009). Many of the recombinant vaccines were
reported to induce strong cellular as well as antibody mediated
immune responses (Rigden et al., 2006; Kathaperumal et al.,
2008; Roupie et al., 2008). Some of the recombinant vaccines also
induced partial protection from infection (Kathaperumal et al.,
2009). At this time no recombinant MAP antigens are used in
commercial vaccines. Therefore, there is a need to evaluate more
MAP antigens to identify potential vaccine candidates.
MAP2698c, a fatty acid dehydrogenase encoded by the desA2
gene, is an ortholog of Rv1094 of Mycobacterium tuberculo-
sis involved in mycobacterial fatty acid metabolism, which is
important for maintaining a robust cell wall, intracellular sur-
vival, growth and pathogenicity (Dyer et al., 2005). MAP3567
is a surface-exposed hypothetical protein overlapped with cell
wall protein (He and De Buck, 2010). Both antigens were
reported to be upregulated under in vitro stress conditions
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(Gumber and Whittington, 2009). In silico analysis suggested
that MAP2698c andMAP3567 proteins contained relatively more
T and B cell epitopes than other stress regulated MAP pro-
teins (Gurung et al., 2012a). These proteins were found to
be detected by antibodies and induced recall of cell mediated
immune responses fromMAP infected sheep suggesting that they
are also expressed under in vivo conditions as they are recognized
by the host immune system. Therefore, we are investigating their
potential immunogenicity as vaccine antigens.
The aim of this study was to evaluate cellular immune response
using interferon-gamma (IFN-γ) release assay as well as humoral
immune response using antibody enzyme linked immunosor-
bent assay (ELISA) in sheep against the recombinant antigens
MAP2698c and MAP3567, when they were administered in




A total of 34 Merino wethers, between 24 and 36 months of
age were sourced from a flock in Armidale, New South Wales,
Australia and moved to the University of Sydney farms. The
source flock was monitored and tested negative for more than 3
consecutive years (MN3) under the Market Assurance Program
for sheep (Animal Health Australia). Among the 34 wethers, 32
were randomly divided into eight groups of four animals for
vaccination and the remaining two sheep were used as unvacci-
nated controls. All animal experiments in this study were carried
out with approval from the University of Sydney Animal Ethics
Committee. During the study the animals were managed under
conventional Australian sheep farming conditions by grazing in
open paddocks.
ANTIGEN AND ADJUVANT
Recombinant MAP antigens, MAP2698c and MAP3567 were
cloned, expressed and purified as previously described (Gurung
et al., 2012b). Four mineral oil based MONTANIDE ISA adju-
vants were used for the formulation of the recombinant vaccines.
The adjuvants were 50V2, 71VG, and 61VG (water in oil for-
mulations) and 201VG (a water in oil in water formulation).
Each recombinant vaccine was formulated by mixing the required
antigen with the selected adjuvants to obtain a 50μg/ml final
concentration of antigen. The required volume of recombinant
vaccine was prepared by mixing antigen and adjuvant at 1:1
ratio (antigen + 50V2, antigen + 201VG); 2:3 ratio (antigen +
61VG) and 3:7 ratio (antigen + 71VG) and vortexed until emul-
sified.
IMMUNIZATION OF ANIMALS
The sheep within the groups were vaccinated with: MAP2698c +
50V2 (group I), MAP2698c + 61VG (group II), MAP2698c +
71VG (group III), MAP2698c + 201VG (group IV),
MAP3567+50V2 (group V), MAP3567+61VG (group VI),
MAP3567+71VG (group VII), MAP3567+201VG (group VIII)
(Table 1). The animals were given 1ml of the required vaccine
formulation by subcutaneous injection behind the left ear on
the upper neck region. Four weeks after primary immunization,
Table 1 | Number of animals with cellular (IFN-γ SP% > 38%) and
humoral immune (antibody SP% > 70%) responses to recombinant
antigen vaccine.




Antigen + adjuvant a b a b
I MAP2698c + 50V2 1 1 0 3
II MAP2698c + 61VG 0 2 0 2
III MAP2698c + 71VG 0 0 0 4
IV MAP2698c + 201VG 0 3 0 2
V MAP3567 + 50V2 1 1 4 4
VI MAP3567 + 61VG 2 3 4 4
VII MAP3567 + 71VG 0 0 3 4
VIII MAP3567 + 201VG 1 0 3 4
a, MAP 316v specific response; b, vaccine antigen specific response; *Four
animals in each group.
a booster was given on the right side of the neck with the same
vaccine.
BLOOD SAMPLING AND INJECTION SITE LESION MONITORING
Blood was collected by venipuncture into lithium-heparin tubes
(9ml) and a tube without anti-coagulant (8ml) (Vacuette®)
on the day of primary vaccination (pre-vaccination) and at 2
week intervals thereafter (post-vaccination) except the final bleed
which had only a 1 week interval. The injection site was inspected
for lesions at the time of blood sample collection. The injection
site areas were palpated and if a lesion was present, its size was
recorded. A Vernier caliper was used to measure one directional
lesion diameter in cm.
IFN-GAMMA ASSAY
Whole blood stimulation
Heparinized blood (500μl per well) was placed in a 48-well plate
(Falcon®) and stimulated with 500μl of antigen at a required final
concentration: 10μg/ml of French pressed whole cell MAP strain
316v (MAP 316v) antigen, 5μg/ml of pokeweedmitogen (PWM);
and 10μg/ml of MAP2698c or MAP3567 recombinant antigen.
The 316v antigen was used for MAP-specific stimulation, PWM
was used as a non-specific stimulant and recombinant MAP anti-
gens were used for antigen-specific stimulation. All antigens were
diluted in culture media containing RPMI 1640, 10% v/v fetal calf
serum (FCS), penicillin, streptomycin, β-mercaptoethanol, and
L-glutamine (GIBCO®, Life Technologies). The negative control
consisted of 500μl of culture medium with 500μl of blood. The
plate was incubated at 37◦C with 5% CO2 for 48 h. The plasma
supernatant was then harvested and stored at −20◦C. All blood
stimulation experiments were set up immediately after each bleed.
IFN-γ ELISA
The IFN-γ ELISA was performed as previously described
(Wood et al., 1990; Begg et al., 2009). Optical density values
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were normalized across plates using the following calculation:
Sample-to-positive (SP)%= [(Mean sample OD)− (Mean nega-
tive control OD)]/[(Mean positive control OD)− (Mean negative
control OD)] × 100.
SERUM ANTIBODY ASSAY
Serum adsorption
The serum was diluted (1:100) in a diluent (0.1% v/v FCS in
PBS 0.05% v/v Tween 20) (FCS in PBST) containing 1.3mg/ml of
heat-killed Mycobacterium phlei (M. phlei) (Elizabeth Macarthur
Agricultural Institute, New South Wales, Australia) and adsorbed
overnight at 4◦Cwith constant end-to-end shaking. The adsorbed
serum was centrifuged at 2500 × g for 10min at room temper-
ature (RT) to separate the supernatant from the particulate M.
phlei.
Serum antibody ELISA
The antibody ELISA was performed using a modified version
of a previously described method (Yokomizo et al., 1983, 1985).
Antigens (MAP 316v, recombinants MAP2698c and MAP3567)
diluted in coating buffer (0.1M carbonate buffer, pH 9.6)
were immobilized onto flat-bottom 96-well microplates (Nunc
MaxiSorp, South Australia, Australia) and incubated overnight at
4◦C. The plate was machine-washed (Tecan, Aim Lab, Victoria,
Australia) 5 times with wash buffer (reverse osmosis water with
tween 0.05% v/v) and then blocked with 100μl/well of a mixture
of 1% v/v FCS (Gibco®, Victoria, Australia) at RT for 30min.
The plate was machine washed 5 times as above. The adsorbed
serum supernatant (50μl) was added to the required wells and
incubated for 1 h at RT. The plate was machine as above prior
to the addition of horse radish peroxidase (HRP)-labeled mouse
anti-sheep monoclonal conjugate (Clone GT-34, Sigma, New
South Wales, Australia) (50μl) (1:40,000) in diluent (0.1% v/v
FCS in PBST), and then incubated for 1 h at RT. The plate was
machine washed as above and 100μl of 3′, 3′, 5′, 5′ tetra-methyl-
benzidine (TMB) substrate was added. The plate was incubated
at RT for 20min in the dark after which the chromogenic
reaction was stopped by the addition of stop solution (50μl of
2M sulphuric acid). The optical density (OD) was measured at
450 nmusing a plate reader (Multiskan Ascent, Thermo Scientific,
Victoria, Australia).
All serum samples were tested after each bleed. The ELISA
result is presented as sample-to-positive (SP) % = [(Mean sam-
ple OD) − (Mean negative control OD)]/[(Mean positive control
OD) − (Mean negative control OD)] × 100.
STATISTICAL ANALYSIS
Significant differences in IFN-γ and antibody responses between
samples collected pre-vaccination and post vaccination were ana-
lyzed by one-way ANOVA with Bonferroni corrections for multi-
ple comparisons in each vaccine group as previously described
(Burton et al., 2009) using GraphPad Prism 4.0 (GraphPad
Software Inc., La Jolla, USA) (P < 0.05, 95% CI). Responses were
also compared between vaccinated and unvaccinated controls.
RESULTS
IFN-γ RESPONSE
The cell mediated immune response to the recombinant vaccine
was evaluated by measuring MAP 316v antigen as well as vac-
cine antigen specific IFN-γ responses. MAP 316v specific IFN-
γ responses of the sheep in response to vaccination with the
formulation of MAP2698c were similar between the adjuvants
(Figure 1A). The sheep vaccinated with MAP3567 + 61VG for-
mulation showed the highest MAP 316v specific IFN-γ responses
among the different formulations (Figure 1B). However, great
variation was observed between the groups of sheep vaccinated
with MAP3567 vaccines depending on the adjuvant.
The vaccine antigen (MAP2698c) specific IFN-γ response
was highest for formulations prepared from MAP2698c + 61VG
and MAP2698c + 201VG (Figure 2A) with the response to
MAP2698c + 201VG formulation at 9 weeks post-vaccination
significantly higher than those pre-vaccination (P < 0.05).
Similarly, formulations prepared from MAP3567 + 61VG
induced the highest vaccine antigen specific IFN-γ responses
followed by the MAP3567 + 50V2 formulation (Figure 2B). The
IFN-γ responses from MAP3567 + 61VG formulation at 4 and
FIGURE 1 | MAP 316v specific IFN-γ responses from recombinant antigen vaccinated sheep. (A) Responses in sheep vaccinated with MAP2698c vaccine;
(B) Responses in sheep vaccinated with MAP3567 vaccine. Data are mean ± SE.
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FIGURE 2 | Vaccine antigen specific IFN-γ responses of sheep vaccinated
with the different formulations of recombinant antigen vaccines. (A)
MAP2698c-specific IFN-γ responses from sheep vaccinated with MAP2698c
+ adjuvants; (B) MAP3567-specific IFN-γ responses from sheep vaccinated
with MAP3567 + adjuvants. Data are mean ± SE. ∗Significantly higher SP%
compared to pre-vaccination (P < 0.05).
9 weeks post-vaccination were significantly higher than those
pre-vaccination (P < 0.05).
SERUM ANTIBODY RESPONSE
The humoral immune response to recombinant vaccine was eval-
uated bymeasuringMAP 316v and vaccine antigen specific serum
antibody levels. MAP 316v antibody responses from sheep vacci-
nated with MAP2698c and all four adjuvant combinations were
not distinguishable from those pre-vaccination or from unvacci-
nated controls (Figure 3A). The MAP 316v antibody responses
from the vaccines formulated with MAP3567 and all four adju-
vants showed significant responses (P < 0.05) which remained
high until 8 weeks post primary vaccination (Figure 3B).
The vaccine antigen specific antibody responses were strong
for MAP2698c (Figure 4A) as well as MAP3567 (Figure 4B) vac-
cines. The formulations of MAP2698c with the four adjuvants
showed similar patterns of vaccine antigen specific antibody
responses, and the response to MAP2698c + 71VG at 6 weeks
post primary vaccination was significantly higher than those
pre-vaccination (P < 0.05). In contrast, antibody responses to
MAP3567 formulations were similar to those of MAP 316v spe-
cific antibody responses. The antibody responses to the formula-
tions of MAP3567 and all four adjuvants were significantly higher
than those pre-vaccination (P < 0.05) at all sampling time-points
(P < 0.05).
PROPORTION OF ANIMALS RESPONDING TO VACCINATION
A recent study conducted to examine the protective level of IFN-
γ response using a validated animal infection model (Begg et al.,
2010) found that an 38% or greater SP of IFN-γ response was
suggestive of a protective response in animals challenged with
live MAP inoculum (de Silva., personal communication). A cut-
point of 70% SP antibody as an indicator of humoral immune
response to exposure was considered. These two thresholds (38%
SP IFN-γ response and 70% SP antibody response) were used to
examine the proportion of animals responding to recombinant
vaccine. The number of animals withMAP 316v and vaccine anti-
gen specific responses above these thresholds is shown in Table 1.
Statistical analysis was not undertaken due to the small group
sizes. A higher proportion of animals showed > 38% SP IFN-
γ response to formulations prepared from MAP2698c + 61VG,
MAP2698c + 201VG, and MAP3567 + 61VG (range: 39–90
SP%). The proportion of animals showing vaccine antigen spe-
cific IFN-γ responses was higher than that of MAP 316v specific
responses. None of the animals that received MAP2698c vaccine
formulations showed MAP 316v specific antibody responses >
70% SP.
INJECTION SITE LESIONS AND LESION PREVALENCE
Lesion prevalence was analyzed for each antigen/adjuvant com-
bination. The majority of the animals (75%) developed injection
site lesions i.e., lesion diameter> 0.5 cm. The animals that devel-
oped the most lesions were those vaccinated with MAP3567 +
61VG (87.5%) and MAP3567 + 201VG (54.2%) as shown in
Figure 5A. Average lesion prevalence in animals vaccinated with
MAP2698c (33%) was lower than in those vaccinated with the
MAP3567 vaccines (45%).
Except for the animals vaccinated with MAP2698c + 61VG,
the mean lesion size for all other adjuvant groups were smaller
than 2.2 cm and decreased over the study period (Figure 5B).
The mean lesion size for MAP2698c + 61VG was 2.35 cm and
rapidly decreased over the study period. In animals that received
MAP2698c + 201VG formulation, the injection site lesions had
completely resolved by the end of the study period. The injection
site lesion recovery in animals that receivedMAP3567 vaccine was
similar between different formulations (Figure 5C). However,
the lesions that developed in response to the MAP3567 vac-
cine were more severe in comparison to those in response to
MAP2698c vaccine. The mean lesion size was greatest for the
MAP3567 + 61VG group and persisted at 1.73 cm until the end of
the study period. Some of these lesions resulted in wool loss and a
discharging sinus at the injection sites in animals vaccinated with
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FIGURE 3 | MAP 316v antibody responses of serum from sheep
vaccinated with the different formulations of recombinant antigen
vaccines. (A) MAP 316v antibody responses in sheep vaccinated with
MAP2698c + adjuvants; (B) MAP 316v antibody responses in sheep
vaccinated with MAP3567 + adjuvants. Data are mean ± SE. ∗Significantly
higher SP% compared to pre-vaccination (P < 0.05).
FIGURE 4 | Vaccine antigen specific antibody responses of serum from
sheep vaccinated with the different formulations of recombinant
antigen vaccines. (A) MAP2698c-specific antibody responses in sheep
vaccinated with MAP2698c + adjuvants; (B) MAP3567-specific antibody
responses in sheep vaccinated with MAP3567 + adjuvants. Data are mean ±
SE. ∗Significantly higher SP% compared to pre-vaccination (P < 0.05).
MAP3567 + 61VG. A higher proportion of animals vaccinated
with vaccine MAP3567 had large lesions compared to those
vaccinated with MAP2698c.
DISCUSSION
The evaluation of recombinant MAP antigens as vaccine candi-
dates in this study was focused on cell mediated and humoral
immune responses in sheep following vaccination with different
formulations prepared from combinations of recombinant anti-
gens and four different adjuvants. Expression of cytokines such
as IFN-γ is believed to contribute to protection against intracel-
lular pathogens including MAP but it is not known what level
of response is adequately protective (Appelberg, 1994; Appelberg
et al., 1994; Stabel, 1996; Chandra et al., 2012). A recent study
using a validated animal infection model has suggested that ani-
mals with an early IFN-γ response of 38% SP or greater are
more likely to be protected against oral challenge with live MAP
(de Silva et al., personal communication). This cut-off was used
in this study to assess the proportion of sheep with an IFN-γ
response. At worst it can be regarded as an arbitrary cut-off. In
this study the recombinant vaccine formulations were found to
induce strong IFN-γ responses, as high as 90% SP, in some vac-
cinated animals. The assessment of the best vaccine formulation
recommneded to carry forward from this study was based on
five criteria: (a) antigen specific IFN-γ response, (b) MAP 316v
specific IFN-γ response, (c) adjuvant effect on IFN-γ response,
(d) injection site lesions and (e) antibody response. Recombinant
vaccine formulated with MAP2698c antigen and 201VG adju-
vant induced stronger MAP 316v as well as recombinant antigen
specific IFN-γ responses in vaccinated animals compared to the
unvaccinated controls and pre-vaccination. The vaccine also pro-
duced lower lesion prevalence and severity compared to other
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FIGURE 5 | Vaccine injection site lesion prevalence and lesion size. (A) Lesion prevalence during the study period; (B) Vaccine formulation (MAP2698c +
adjuvants) lesion size and trend; and (C) Vaccine formulation (MAP3567 + adjuvants) lesion size and trend. Data are mean ± SE.
formulations. The antibody response was slightly lower from this
formulation, and antibody is thought to play a lesser role in
protection against MAP infections (Rosseels and Huygen, 2008).
Lesions at the vaccine injection site have been observed in a
high proportion of animals following vaccination against paratu-
berculosis (Sigurdsson and Tryggvadottir, 1950; Chiodini et al.,
1984; Windsor and Eppleston, 2006). Lesions are thought to be
caused by the oil-based adjuvants which are non-absorbable, act
as irritants and increase antigen persistence to induce sustained
immune responses (Hope, 1995). In lambs that received Gudair™
vaccine, 65% of them developed injection site lesions and these
lesions persisted for up to 4 years in 20% of the vaccinated
animals (Eppleston and Windsor, 2007). The lesion prevalence
and sizes in this study were monitored for a 9 week period fol-
lowing primary vaccination and were observed to be decreasing
post-vaccination. The formulation MAP3567 and the adjuvant
MONTANIDE™ ISA 61VG resulted in a high proportion of
sheep with severe lesions. This formulation may not qualify as a
vaccine candidate on animal welfare grounds due to the initial
high number of large lesions and the possibility of downgrad-
ing carcass value at slaughter. These data also indicate that it is
not just the adjuvants that are responsible for the injection site
lesions but the combination between adjuvant and antigen. Sheep
vaccinated with the MAP2698c formulation showed substantial
levels of IFN-γ responses in a high proportion of vaccinated ani-
mals and low prevalence of injection site lesions. The vaccine
formulated withMAP3567 showed a strong antibody response for
all adjuvant groups and caused more severe lesions.
The findings from this study suggest that MAP2698c and
MAP3567 antigens may have potential as candidate antigens for
cell mediated and antibody mediated immune response stud-
ies, respectively. These findings are also supported by a previous
study in which we reported the presence of a greater number of
T cell epitopes for the MAP2698c protein and a greater number
of B cell epitopes for the MAP3567 protein compared to other
proteins (Gurung et al., 2012a). Antigenicity of these antigen
was confirmed in clinically infected sheep Gurung et al. (2012b).
Furthermore, MAP3567 is reported to be a surface-exposed pro-
tein overlapped with the cell wall proteins that may be more
accessible to circulating antibodies and effect antigen-antibody
binding to clear pathogens in natural infection conditions (He
and De Buck, 2010). Sheep vaccinated with MAP2698c antigen
were not able to produce MAP 316v specific antibodies. However,
we previously reported that MAP2698c antigen is able to be used
to detect specific antibodies from MAP infected sheep (Gurung
et al., 2012b). These findings suggest that the MAP 316v antigen
may either not contain MAP2698c protein or it is not in a form
that can be recognized by the serum antibodies from MAP2698c
vaccinated sheep.
Due to the likely protective immune function of IFN-γ and the
relatively lower degree of lesion development at the site of vaccine
injection from MAP2698c + 201VG vaccine compared to that of
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other formulations, this vaccine should be evaluated further in
sheep. A longitudinal study in a larger cohort of animal is required
to evaluate whether it induces protective immunity against MAP
infection.
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